Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Operating Income (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Operating Income readings, the most recent being $8.3 million for Q4 2025.

  • On a quarterly basis, Operating Income rose 1527.54% to $8.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$187.3 million, a 88.91% decrease, with the full-year FY2025 number at -$187.3 million, down 88.91% from a year prior.
  • Operating Income hit $8.3 million in Q4 2025 for Tandem Diabetes Care, up from -$22.9 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $12.7 million in Q4 2021 to a low of -$127.8 million in Q1 2023.
  • Median Operating Income over the past 5 years was -$24.5 million (2024), compared with a mean of -$29.5 million.
  • Biggest five-year swings in Operating Income: tumbled 733.34% in 2023 and later surged 1527.54% in 2025.
  • Tandem Diabetes Care's Operating Income stood at $12.7 million in 2021, then crashed by 239.56% to -$17.8 million in 2022, then tumbled by 97.22% to -$35.1 million in 2023, then skyrocketed by 98.34% to -$581000.0 in 2024, then surged by 1527.54% to $8.3 million in 2025.
  • The last three reported values for Operating Income were $8.3 million (Q4 2025), -$22.9 million (Q3 2025), and -$51.8 million (Q2 2025) per Business Quant data.